SG11202105745UA - Crystalline forms of a compound for treating or preventing gout or hyperuricemia - Google Patents
Crystalline forms of a compound for treating or preventing gout or hyperuricemiaInfo
- Publication number
- SG11202105745UA SG11202105745UA SG11202105745UA SG11202105745UA SG11202105745UA SG 11202105745U A SG11202105745U A SG 11202105745UA SG 11202105745U A SG11202105745U A SG 11202105745UA SG 11202105745U A SG11202105745U A SG 11202105745UA SG 11202105745U A SG11202105745U A SG 11202105745UA
- Authority
- SG
- Singapore
- Prior art keywords
- hyperuricemia
- treating
- compound
- crystalline forms
- preventing gout
- Prior art date
Links
- 201000005569 Gout Diseases 0.000 title 1
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018119567 | 2018-12-06 | ||
| PCT/US2019/064784 WO2020118113A1 (en) | 2018-12-06 | 2019-12-05 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105745UA true SG11202105745UA (en) | 2021-06-29 |
Family
ID=70974392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105745UA SG11202105745UA (en) | 2018-12-06 | 2019-12-05 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12145917B2 (https=) |
| EP (1) | EP3890723A4 (https=) |
| JP (2) | JP2022511800A (https=) |
| KR (1) | KR102946486B1 (https=) |
| CN (1) | CN113226302B (https=) |
| AU (1) | AU2019394974B2 (https=) |
| BR (1) | BR112021010708A2 (https=) |
| EA (1) | EA202191545A1 (https=) |
| IL (1) | IL283663B2 (https=) |
| SG (1) | SG11202105745UA (https=) |
| TW (1) | TWI828817B (https=) |
| WO (1) | WO2020118113A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4349414B1 (en) | 2014-12-23 | 2025-10-15 | Dyve Biosciences, Inc. | Formulations for transdermal administration |
| EP3484862B1 (en) | 2016-07-18 | 2021-09-01 | Arthrosi Therapeutics, Inc. | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia |
| EP3681479B1 (en) | 2017-09-15 | 2024-01-31 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| SG11202105743RA (en) | 2018-12-06 | 2021-06-29 | Arthrosi Therapeutics Inc | Methods for treating or preventing gout or hyperuricemia |
| KR102946486B1 (ko) | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| WO2020232156A1 (en) * | 2019-05-14 | 2020-11-19 | Arthrosi Therapeutics, Inc. | Compound for treating gout or hyperuricemia |
| KR20230024354A (ko) * | 2020-06-10 | 2023-02-20 | 아쓰로시 테라퓨틱스, 인크. | 만성 신장 질환을 치료 또는 예방하는 방법 |
| TW202330485A (zh) * | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | 用於治療或預防痛風或高尿酸血症之化合物的結晶形式 |
| WO2023125667A1 (en) * | 2021-12-30 | 2023-07-06 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| CZ282760B6 (cs) | 1991-11-22 | 1997-09-17 | Procter And Gamble Pharmaceuticals, Inc. | Risedronátové prostředky se zpožděným uvolňováním |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE69332291T2 (de) | 1992-10-16 | 2003-07-31 | Nippon Shinyaku Co., Ltd. | Verfahren zur herstellung von wachsmatrizes |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| DE19624292A1 (de) | 1996-06-18 | 1998-01-02 | Merckle Gmbh | Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| WO2005121112A1 (ja) | 2004-06-10 | 2005-12-22 | Torii Pharmaceutical Co., Ltd. | ６－ヒドロキシベンズブロマロン又はその塩からなる医薬組成物 |
| US20080305169A1 (en) | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
| CN101765582A (zh) | 2007-04-26 | 2010-06-30 | 奥斯拜客斯制药有限公司 | 氘标记的氯胺酮 |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| US8791077B2 (en) | 2008-05-22 | 2014-07-29 | Astrazeneca Ab | Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same |
| JP5325065B2 (ja) | 2009-09-30 | 2013-10-23 | 株式会社富士薬品 | 新規フェノール誘導体 |
| IT1400609B1 (it) | 2010-05-10 | 2013-06-14 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e metformina e loro uso. |
| US10005750B2 (en) | 2010-10-06 | 2018-06-26 | J-Pharma Co., Ltd. | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action |
| US20150031768A1 (en) | 2011-08-19 | 2015-01-29 | The Trustees Of Princeton University | C-halogen bond formation |
| US9060987B2 (en) | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
| US9962362B2 (en) | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| JO3754B1 (ar) | 2012-06-04 | 2021-01-31 | Pharmacyclics Llc | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون |
| WO2014113407A2 (en) | 2013-01-16 | 2014-07-24 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting eya tyrosine phosphatase |
| WO2014149789A1 (en) | 2013-03-15 | 2014-09-25 | Janssen Pharmaceutica Nv | Combination of canagliflozin and probenecid for the treament of hyperuricemia |
| WO2014194226A2 (en) | 2013-05-31 | 2014-12-04 | Takeda Pharmaceuticals U.S.A., Inc. | Methods of treatment and compositions with xanthine oxidase inhibitors |
| WO2015134467A1 (en) | 2014-03-05 | 2015-09-11 | The Trustees Of Princeton University | Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks |
| CN107001356B (zh) | 2014-07-31 | 2019-09-03 | 默克专利有限公司 | 用于神经退化性疾病的中氮茚衍生物 |
| CN104262305B (zh) * | 2014-09-16 | 2016-06-08 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型a及其制备方法 |
| CN104311516B (zh) * | 2014-09-16 | 2017-01-11 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型b及其制备方法 |
| EP3484862B1 (en) | 2016-07-18 | 2021-09-01 | Arthrosi Therapeutics, Inc. | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia |
| WO2018090921A1 (zh) | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| KR101964435B1 (ko) | 2016-12-14 | 2019-04-01 | 주식회사 엘지화학 | 헤테로 고리 화합물 및 이를 포함하는 유기 발광 소자 |
| US20210130312A1 (en) | 2018-04-03 | 2021-05-06 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| WO2019233459A1 (zh) | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | 人表皮生长因子受体抑制剂及其制备方法和应用 |
| MX2021003845A (es) | 2018-10-01 | 2021-05-27 | Astrazeneca Ab | Composiciones para reducir el acido urico serico. |
| SG11202105743RA (en) | 2018-12-06 | 2021-06-29 | Arthrosi Therapeutics Inc | Methods for treating or preventing gout or hyperuricemia |
| KR102946486B1 (ko) | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| EP3962908A4 (en) | 2019-04-25 | 2022-10-26 | Board of Regents, The University of Texas System | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE |
| WO2020232156A1 (en) | 2019-05-14 | 2020-11-19 | Arthrosi Therapeutics, Inc. | Compound for treating gout or hyperuricemia |
| CN112079830B (zh) | 2019-06-14 | 2023-12-22 | 上海翰森生物医药科技有限公司 | 含并环类衍生物抑制剂、其制备方法和应用 |
| KR20230024354A (ko) | 2020-06-10 | 2023-02-20 | 아쓰로시 테라퓨틱스, 인크. | 만성 신장 질환을 치료 또는 예방하는 방법 |
| CN111763215B (zh) | 2020-07-21 | 2021-05-18 | 成都海博为药业有限公司 | 一种具有含氮杂环结构的化合物及其制备方法和用途 |
| CN112729156A (zh) | 2020-12-24 | 2021-04-30 | 上海智能制造功能平台有限公司 | 一种人体数字化测量装置的数据拼接及系统标定方法 |
| CN114697265A (zh) | 2020-12-29 | 2022-07-01 | 华为技术服务有限公司 | 一种报文处理方法及装置 |
| JP2024532249A (ja) | 2021-08-24 | 2024-09-05 | アースローシ セラピューティクス，インク． | 疾患の処置のためのキナゾリン化合物 |
| TW202330485A (zh) * | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | 用於治療或預防痛風或高尿酸血症之化合物的結晶形式 |
| WO2023125667A1 (en) | 2021-12-30 | 2023-07-06 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
-
2019
- 2019-12-05 KR KR1020217021172A patent/KR102946486B1/ko active Active
- 2019-12-05 EP EP19893127.1A patent/EP3890723A4/en active Pending
- 2019-12-05 WO PCT/US2019/064784 patent/WO2020118113A1/en not_active Ceased
- 2019-12-05 AU AU2019394974A patent/AU2019394974B2/en active Active
- 2019-12-05 SG SG11202105745UA patent/SG11202105745UA/en unknown
- 2019-12-05 EA EA202191545A patent/EA202191545A1/ru unknown
- 2019-12-05 JP JP2021531047A patent/JP2022511800A/ja active Pending
- 2019-12-05 US US17/311,249 patent/US12145917B2/en active Active
- 2019-12-05 CN CN201980080515.8A patent/CN113226302B/zh active Active
- 2019-12-05 IL IL283663A patent/IL283663B2/en unknown
- 2019-12-05 BR BR112021010708-8A patent/BR112021010708A2/pt unknown
- 2019-12-06 TW TW108144814A patent/TWI828817B/zh active
-
2024
- 2024-10-11 US US18/913,928 patent/US20250059150A1/en active Pending
- 2024-10-25 JP JP2024188449A patent/JP2025026857A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3121913A1 (en) | 2020-06-11 |
| IL283663B1 (en) | 2025-08-01 |
| CN113226302B (zh) | 2023-08-18 |
| CN113226302A (zh) | 2021-08-06 |
| JP2025026857A (ja) | 2025-02-26 |
| EA202191545A1 (ru) | 2021-10-28 |
| KR20210100677A (ko) | 2021-08-17 |
| TW202039453A (zh) | 2020-11-01 |
| AU2019394974A1 (en) | 2021-07-15 |
| JP2022511800A (ja) | 2022-02-01 |
| EP3890723A4 (en) | 2022-08-03 |
| WO2020118113A1 (en) | 2020-06-11 |
| IL283663B2 (en) | 2025-12-01 |
| EP3890723A1 (en) | 2021-10-13 |
| US20250059150A1 (en) | 2025-02-20 |
| BR112021010708A2 (pt) | 2021-08-24 |
| AU2019394974B2 (en) | 2025-08-28 |
| IL283663A (en) | 2021-07-29 |
| US20220024889A1 (en) | 2022-01-27 |
| US12145917B2 (en) | 2024-11-19 |
| KR102946486B1 (ko) | 2026-03-31 |
| TWI828817B (zh) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283663A (en) | Crystalline forms of a compound for the treatment or prevention of rheumatism or hyperuricemia | |
| SG11202112562XA (en) | Compound for treating gout or hyperuricemia | |
| IL257960A (en) | A group of substances used to treat or prevent hyperuricemia or gout | |
| PL4055021T3 (pl) | Heterocykliczne związki hamujące RIP1 | |
| IL283665A (en) | Methods for treating or preventing rheumatism or hyperuricemia | |
| HUE064943T2 (hu) | Szubsztituált tiazolidin vegyület alkalmazása nitrifikációs inhibitorként | |
| IL289929A (en) | Crystal forms of cd73 inhibitor | |
| ZA202103106B (en) | Heterocyclic compounds for the treatment of epilepsy | |
| ZA202006134B (en) | Oxazole compound crystal | |
| IL281168A (en) | Crystal forms of the quinazole compound and its hydrochloride salts | |
| IL285219A (en) | A crystal of the compound diarylthiohydantoin | |
| IL284564A (en) | Polymorphic forms of a modified quinoline-type bridged piperidine compound | |
| ZA202007034B (en) | The crystalline forms of a compound | |
| GB201814067D0 (en) | Compounds for the inhibition of cyclophilins | |
| IL292206A (en) | The salts of a compound and its crystalline forms | |
| SG11202105355XA (en) | Crystalline salts of corydalmine | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| SG11202009262VA (en) | Salts of compounds and crystals thereof | |
| KR102623532B9 (ko) | 납-금속 화합물 단결정의 개질방법 | |
| IL317157A (en) | Solid formulations of a compound for treating or preventing hyperuricemia or gout | |
| GB201915908D0 (en) | Crystalline forms of entrectinib | |
| HK40051477A (en) | Heterocyclic compounds for the treatment of epilepsy | |
| SG11202106561RA (en) | Crystalline forms of a par4 inhibitor |